PATENT COOPERATION TRANSTY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To

Assistant Commissioner for Patents United States Patent and Trademark Office Box PCT Washington, D.C.20231 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
27 July 2000 (27.07.00)

International application No.
PCT/US99/26277

International filing date (day/month/year)
05 November 1999 (05.11.99)

Applicant

BLASZCZYK-THURIN, Magdalena et al

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	01 June 2000 (01.06.00)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Diana Nissen

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

PATENT COOPERATION TREATY

PCT

REO'D	0 9	MAR	2001
	•		

FOT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WST99PCT	FOR FURTHER ACTION	Prelimina	ation of Transmittal of International ry Examination Report (Form
	International filing date (day/	month/year)	Priority date (day/month/year)
International application No.	05 NOVEMBER 1999		06 NOVEMBER 1998
PCT/US99/26277 International Patent Classification (IPC)		PC	
International Patent Classification (IFC) IPC(7): A61K 58/10 and US Cl.: 514	/2, 14, 15		
Applicant THE WISTAR INSTITUTE OF ANA	ATOMY AND BIOLOGY		
Examining Authority and is	transmitted to the applicant	been prepar t according to	red by this International Preliminary Article 36.
2. This REPORT consists of a	total of sheets.		
This report is also acconbeen amended and are to (see Rule 70.16 and Section	npanied by ANNEXES, i.e., sh he basis for this report and or s tion 607 of the Administrative	посе сопини	cription, claims and/or drawings which have ng rectifications made before this Authority. Inder the PCI').
These annexes consist of a to	otal of <u>f</u> sheets.		
3. This report contains indication		items:	
I X Basis of the rep	ort		
II Priority			
III Non-establishm	ent of report with regard to	novelty, inven	tive step or industrial applicability
IV Lack of unity of	f invention		
V X Reasoned stateme	ent under Article 35(2) with re lanations supporting such state	gard to novelt ment	y, inventive step or industrial applicability;
VI Certain document	s cited		
VII Certain defects in	the international application		
VIII Certain observation	ons on the international applic	ation	
Date of submission of the demand	D	ate of complet	on of this report
01 JUNE 2000		o FEBRUA	RY 2001
	24.415	uthorized offic	El Dadannol
Name and mailing address of the IPE Commissioner of Patents and Tra	LA/C3	Joy	e Brain
Commissioner of Patents and 17st Box PCT		VID LUI	KTON
Washington, D.C. 20231		//	/1

International application No.


	the report	
1 11/44	to the elements of the international application	on:*
	ternational application as originally fi	led l
1 X I	escription:	, as originally filed
pages		, filed with the demand
	NONE	, filed with the letter of
pages	NONE	, med with the letter of
Y the cl	aime.	u mi t
	57 62	, as originally filed
	NONE	, as amended (together with any statement) under Article 19
_		, filed with the demand
	NONE , filed v	with the letter of
P. B.		
X the di	rawings:	as originally filed
ستا pages	1-5	, as originally filed
	NONE	, inca with the
	NONE	, filed with the letter of
X the se	equence listing part of the description:	, as originally filed
page		
page	s <u>NONE</u>	, filed with the letter of
page	sNONE	, filed with the letter of
uie ii	anguage of a translation furnished 131	the purposes of international search (under Rule 23.1(b)).
	anguage of publication of the internat	ional application (under Rule 48.3(b)).
the la	anguage of publication of the internat anguage of the translation furnished for the	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and
the le	anguage of publication of the internat anguage of the translation furnished for the i.3).	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international
the le or 55 With reg prelimin	anguage of publication of the internat anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino ac ary examination was carried out on the	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing:
the late or 55 3. With reg prelimin X cont	anguage of publication of the internat anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino ac ary examination was carried out on the ained in the international application	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form.
the le or 55 3. With reg prelimin X cont	anguage of publication of the internation anguage of the translation furnished for the i.3). and to any nucleotide and/or amino acary examination was carried out on the ained in the international application.	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing in printed form. cation in computer readable form.
the late or 55 3. With reg prelimin X cont filed furn	anguage of publication of the internation anguage of the translation furnished for the i.3). and to any nucleotide and/or amino ac- ary examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n written form.
the late or 55 3. With reg prelimin X cont filed	anguage of publication of the internation anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino accuracy examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n written form. n computer readable form.
the late or 55 3. With reg prelimin X cont filed furn furn The	anguage of publication of the internation anguage of the translation furnished for the i.3). and to any nucleotide and/or amino accuracy examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is ished subsequently to this Authority is statement that the subsequently furnish arctional application as filed has been for	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n written form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished.
the late or 55 3. With reg prelimin X cont filed furn furn The	anguage of publication of the internation anguage of the translation furnished for the i.3). and to any nucleotide and/or amino accuracy examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is ished subsequently to this Authority is statement that the subsequently furnish arctional application as filed has been for	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n written form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the
the late or 55 3. With reg prelimin X cont filed furn furn The inter The beer	anguage of publication of the internation anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino accary examination was carried out on the ained in the international application. It together with the international application ished subsequently to this Authority is ished subsequently to this Authority is statement that the subsequently furnishmational application as filed has been for statement that the information recorded in furnished.	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. n computer readable form is identical to the writen sequence listing has
the late or 55 3. With reg prelimin	anguage of publication of the internation anguage of the translation furnished for the internation and to any nucleotide and/or amino accary examination was carried out on the ained in the international application and together with the international application is shed subsequently to this Authority is is a subsequently to this Authority is statement that the subsequently furnishmational application as filed has been for statement that the information recorded in furnished.	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. eation in computer readable form. In computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. In computer readable form is identical to the writen sequence listing has
the late or 55 3. With reg prelimin X cont filed furn furn The inter The beer	anguage of publication of the international anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino accuracy examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is statement that the subsequently furnishmational application as filed has been for statement that the information recorded in furnished. The amendments have resulted in the case the description, pages NONE	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. n computer readable form is identical to the writen sequence listing has
the late or 55 3. With reg prelimin	anguage of publication of the internation anguage of the translation furnished for the initial state of the initial state of any nucleotide and/or amino accuracy examination was carried out on the ained in the international application together with the international application is shed subsequently to this Authority is statement that the subsequently furnish mational application as filed has been for statement that the information recorded in furnished. The description, pages NONE the claims, Nos. NONE	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n written form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. n computer readable form is identical to the writen sequence listing has
the late or 55 3. With reg prelimin X cont filed furn The inter 4 X X X X The late X X X The late X X X The late X X X The late X X X The late X X X The late X X X The late X X X The late X X X The late X X X The late X The late X X The late The late X The late X The late The late X X The late The late X The late T	anguage of publication of the international anguage of the translation furnished for the i.3). ard to any nucleotide and/or amino accuracy examination was carried out on the ained in the international application I together with the international application ished subsequently to this Authority is ished subsequently to this Authority is statement that the subsequently furnishmational application as filed has been for statement that the information recorded in furnished. The description, pages NONE the description sheets/fig.	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. In written form. The computer readable form of the written sequence listing does not go beyond the disclosure in the urnished. The computer readable form is identical to the written sequence listing has incellation of:
the late or 55 3. With reg prelimin X cont filed furn furn The inter X X X 5. The	anguage of publication of the internation anguage of the translation furnished for the initial anguage of the translation furnished for the initial anguage examination was carried out on the ained in the international application and together with the international application is the distribution and subsequently to this Authority is statement that the subsequently furnish mational application as filed has been for statement that the information recorded in furnished. The description, pages NONE the claims, Nos NONE NONE NONE The drawings, sheets/fig NONE is report has been drawn as if (some of) the internation of the internation of the internation in the claims of the claims of the internation of the inte	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. In computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. In computer readable form is identical to the writen sequence listing has incellation of: e amendments had not been made, since they have been considered to go the Supplemental Roy (Rule 70.3(c)) **
the late or 55 3. With reg prelimin	anguage of publication of the international anguage of the translation furnished for the initial anguage of the translation furnished for the initial anguage examination was carried out on the ained in the international application and together with the international application is the discharge examination and application at the subsequently to this Authority is statement that the subsequently furnish mational application as filed has been for statement that the information recorded in furnished. The description, pages NONE the claims, Nos. NONE NONE the drawings, sheets/fig NONE is report has been drawn as if (some of) the twood the disclosure as filed, as indicated in the claims.	ional application (under Rule 48.3(b)). e purposes of international preliminary examination (under Rules 55.2 and id sequence disclosed in the international application, the international basis of the sequence listing: in printed form. cation in computer readable form. n computer readable form. ed written sequence listing does not go beyond the disclosure in the urnished. n computer readable form is identical to the writen sequence listing has incellation of: ———————————————————————————————————

International application No.

etata	ment			
		Claims	3-41	_ YE
N	lovelty (N)	Claims	1-9	_ NO
			3-41	YE
Ľ	nventive Step (IS)	Claims Claims	1-9	_ NO
		Claims		
		at :	1-41	_ YE
I	ndustrial Applicability (IA)	Claims	NONE	_ NO
		Claims	NONE	_
Heav	ner teaches (col 4, line 42+) peptides line 7+) pharmaceutical composition	which inhibit (g anticipated by Heavner (USP 5464935). col 1, lines 9-10) binding of selectins. The reference also des; the peptides are effective to modulate binding of selective to encompass the peptides disclosed by Heavner; the cla	ctins t
The				
recept anticip	ors or ligands. The claims are of pated.	sufficient scope	to encompass one paper.	
recept anticip	ors or ligands. The claims are of pated.	PCT Article 33(e to encompass the peptides disclosed by Meaviler, the original state of the prior art does not teach or fairly sugges	
recept anticip Claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I	PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
recept anticip Claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in Ed compositions or associated method ms 1-41 meet the criteria set out in 1	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
recept anticip Claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
recept anticip Clain claime Clai	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
Claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	
claime	ors or ligands. The claims are of pated. ms 3-41 meet the criteria set out in I and compositions or associated method ms 1-41 meet the criteria set out in I need the criteria set out in	SUMICIENT SCOPE PCT Article 33(PCT Article 33(2)-(3), because the prior art does not teach or fairly sugge	

International application No.

tinuation of: Boxes I - VIII	Sheet 10



IPEA/_US

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:

The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

Identification of IPEA	_	Date of receipt of I	EMAND
Box No. I IDENTIFICATION OF T	HE INTERNATIONAL	APPLICATION	Applicant's or agent's file reference WST93PCT
nternational application No. PCT/US99/26277 International filing date (date		(day/month/year)	(Earliest) Priority date (day/month/year)
			06 November 1998
Title of invention			
COMPOSITIONS AND M	ETHODS FOR TR	EATMENT OF	CANCER
Box No. II APPLICANT(S)			
Name and address: (Family name followed by The address must include j	given name; for a legal entity,	full official designation.	Telephone No.:
The address must include	postal code and name of country,	ology	215-898-3763
The Wistar Institute of	Anatomy and bic)±091	Facsimile No.:
3601 Spruce Street Philadelphia, Pennsylvar	nia 19104		215–573–2456
Jnited States of America	a		Teleprinter No.:
State (that is, country) of nationality: United States Name and address: (Family name followed by	gwen name; for a legal entity, f	State (that is, coun United Sta	tes e address must include postal code and name of country:)
The Trustees of the Un 3700 Market Street, Su Philadelphia, Pennsylv	ite 300 ania 19104-314		
2700 Market Street, Su	ite 300 ania 19104-314	7	
3700 Market Street, Su Philadelphia, Pennsylv United States of Ameri State (that is, country) of nationality:	ite 300 ania 19104-314	State (that is, cou	nny) of residence:
3700 Market Street, Su Philadelphia, Pennsylv United States of Ameri State (that is, country) of nationality: United States	ite 300 ania 19104-314 ca y given name, for a legal entity, dalena yania 19104	State (that is, cou	

Sheet No. 2

International application No. PCT/US99/26277

Continuation of Box No. II APPLICANT(S)	
If none of the following sub-boxes is used, th	is sheet should not be included in the demand.
Name and address: (Family name followed by given name; for a legal entity: f Kieber-Emmons, Thomas 3231 Saw Mill Road Newtown Square, Pennsylvania 19073 United States of America	full official designation. The address must include postal code and name of country:)
State (that is, country) of nationality: United States	State (that is, country) of residence: United States
State (that is, country) of nationality:	State (that is, country) of residence:
Name and address: (Family name followed by given name; for a legal entity, fin	ll official designation. The address must include postal code and name of country:)
State (that is, country) of nationality:	State (that is, country) of residence:
Name and address. (Family name followed by given name; for a legal entity, full	I official designation. The address must include postal code and name of country:)
State (that is, country) of nationality:	State (that is, country) of residence.
Further applicants are indicated on another continuation shee	et.

Sheet No. 3

International application No. PCT/US99/26277

	101/0033/20277					
Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CO	PRRESPONDENCE					
The following person is X agent common representative						
and X has been appointed earlier and represents the applicant(s) also for international preliminary examination.						
is hereby appointed and any earlier appointment of (an) agent(s)/common represe	ntative is hereby revoked.					
is hereby appointed, specifically for the procedure before the International Prelim the agent(s)/common representative appointed earlier.	inary Examining Authority, in addition to					
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	Telephone No.:					
Bak, Mary E.	215-540-9200					
Howson and Howson Facsimile No.:						
Spring House Corporate Center	215-540-5818					
P.O. Box 457 Spring House, Pennsylvania 19477						
United States of America	Teleprinter No.:					
Address for correspondence: Mark this check-box where no agent or common re space above is used instead to indicate a special address to which correspondence	presentative is/has been appointed and the should be sent.					
Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION						
Statement concerning amendments: *						
1. The applicant wishes the international preliminary examination to start on the basis of:						
the international application as originally filed						
the description as originally filed						
as amended under Article 34						
the claims as originally filed						
as amended under Article 19 (together with any accompanying	statement)					
as amended under Article 34	,					
the drawings as originally filed						
as amended under Article 34						
2 The applicant wishes any amendment to the claims under Article 19 to be considered.	ed as reversed.					
3. The applicant wishes the start of the international preliminary examination to be position the priority date unless the International Preliminary Examining Authority reunder Article 19 or a notice from the applicant that he does not wish to make such a box may be marked only where the time limit under Article 19 has not yet expired.)	ceives a copy of any amendments made mendments (Rule 69.1(d)). (This check-					
• Where no check-box is marked, international preliminary examination will start on the as originally filed or, where a copy of amendments to the claims under Article 19 and/or am under Article 34 are received by the International Preliminary Examining Authority before or the international preliminary examination report, as so amended.	endments of the international application. I					
Language for the purposes of international preliminary examination: English						
X which is the language in which the international application was filed.						
which is the language of a translation furnished for the purposes of international	il search.					
which is the language of publication of the international application.						
which is the language of the translation (to be) furnished for the purposes of in	ternational preliminary examination.					
Box No. V ELECTION OF STATES						
The applicant hereby elects all eligible States (that is, all States which have been designated the PCT)	l and which are bound by Chapter II of					
excluding the following States which the applicant wishes not to elect:						
and the applicant wishes not as eject:						

Sheet	NT.	4
Sheet	No	-

International application No. PCT/US99/26277

The demand is accompanied by the following ele Box No. IV, for the purposes of international pr	ments, in the la eliminary exar	inguage referred to in nination:	Examining A	ional Preliminary Authority use only
			received	not received
1. translation of international application	:	sheets		
2. amendments under Article 34	÷	sheets		
3. copy (or, where required, translation) of amendments under Article 19	÷	sheets		
copy (or, where required, translation) of statement under Article 19				
statement under Milete 19	•	sheets		LJ
5. letter	*	sheets		
6. other (specify)	:	shects		
he demand is also accompanied by the item(s) ma	irked below:			
1. X fee calculation sheet		4. statement ex	plaining lack of sign	ature
2. separate signed power of attorney			nd or amino acid seq	uence listing in
3. copy of general power of attorney; reference number, if any:		computer rea		
reference number, if any:		6. other (specify	v):	
			-, ,	
ox No. VII SIGNATURE OF APPLICANT, A real to each signature, indicate the name of the person signing of				om reading the demand).
	and the capacity in			om reading the demand).
By: Moy E. Bak Mary E. Pak Attorney for Applicant	and the capacity in	which the person signs (if such	i capacity is not obvious fi	om reading the demand).
By: Moy E. Bak Mary E. Pak Attorney for Applicant	and the capacity in		i capacity is not obvious fi	iom reading the demand).
By: Moy E. Bak Mary E. Bak Attorner for Applicant	and the capacity in	which the person signs (if such	i capacity is not obvious fi	iom reading the demand).
By: Mary E. Bak Attorney for Applicant For Internation 1. Date of actual receipt of DEMAND:	al Preliminary	Examining Authority use	i capacity is not obvious fi	has been
By: Mary E. Bak Attorney for Applicant For Internation Date of actual receipt of DEMAND: Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b): The date of receipt of the demand is AFT	al Preliminary TER the expira	Examining Authority use	The applicant informed acco	has been ordingly.
By: Mary E. Bak Attorney for Applicant For Internation 1. Date of actual receipt of DEMAND: 2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b): The date of receipt of the demand is AFT from the priority date and item 4 or 5. b	al Preliminary TER the expira elow, does no	Examining Authority use tion of 19 months apply.	The applicant informed according to the priority date as	has been ordingly.

PATENT COOPERATION TREATY

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY **PCT** MARY E. BAK HOWSON AND HOWSON SPRING HOUSE CORPORATE CENTER WRITTEN OPINION P.O. BOX 457 SPRING HOUSE, PA 19477 (PCT Rule 66) SEP 1 1 2000 Date of Mailing 07 SEP 2000 (day/month/year) Applicant's or agent's file reference REPLY DUE within TWO months WST93PCT from the above date of mailing International application No. International filing date (day/month/year) Priority date (day/month/year) --PCT/US99/26277 **05 NOVEMBER 1999** 06 NOVEMBER 1998 International Patent Classification (IPC) or both national classification and IPC IPC(7): A61K 38/10 and US Cl.: 514/2, 14, 15 THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY 1. This written opinion is the first _ (first, etc.) drawn by this International Preliminary Examining Authority. 2. This opinion contains indications relating to the following items: Basis of the opinion H Priority Ш Non-establishment of opinion with regard to novelty, inventive step or industrial applicability Lack of unity of invention Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI Certain documents cited VII Certain defects in the international application VIII Certain observations on the international application 3. The applicant is hereby invited to reply to this opinion. When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension., see Rule 66.2(d). How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9. Also For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis. For an informal communication with the examiner, see Rule 66.6. If no reply is filed, the international preliminary examination report will be established on the basis of this opinion. 4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 06 MARCH 2001

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Telephone No.

DAVID LUKTON

(703) 308-0196

WRITTEN OPINION

International application No.

I. B	asis (of the opinio	on				
1. Witi	h rega	rd to the elem	ents of the interna	ational applicati	an:*		
X			application as				
X	ı	description:	• •				
LX		-	1-56				, as originally filed
							, filed with the demand
	pag	es					
_							
X		claims:	57-63				
							, as originally filed (attement) under Article 19
						-	, filed with the demand
			NONE	, filed w	ith the letter of		, med with the demand
				 , ′	•		
\mathbf{x}	the	drawings:					
							, as originally filed
							, filed with the demand
	page	es	NONE		, filed with the lette	r of	
\overline{x}	the s	sequence list	ing part of the d	escription:			
LA			• •	=			, as originally filed
	page	:s t	NONE				, filed with the demand
	page	esN	ONE		, filed with the letter	r of	
	the l	anguage of a anguage of p unguage of the	translation fur publication of t	rnished for th he internation	e purposes of internanal application (under	tional search (ur Rule 48.3(b)).	which is: nder Rule 23.1(b)). nination (under Rules 55.2 and/
			eleotide and/or a the sequence list		uence disclosed in the	international applic	cation, the written opinion was
X	contr	sined in the	international ap	anlication in	printad form		
Щ	mea	together wi	in the internation	onal applicati	on in computer reada	ible form.	
	furni	shed subsequ	uently to this ∧	cuthority in w	ritten form.		
	furni	shed subsequ	uently to this Δ	authority in e	omputer readable for:	m.	
	The s	statement tha national appli	t the subsequent cation as filed b	tly furnished v nas been furni	written sequence listing shed.	g does not go be	yond the disclosure in the
	The s been	tatement that furnished.	the information	recorded in co	mputer readable form i	s identical to the	writen sequence listing has
4. X	The	amendments	have resulted	in the cancel	lation of:		
ريبتا ٠٠	X			NONE			
		the descrip					
		the claims,	· · · · · · · · · · · · · · · · · · ·	NONE			
		the drawing	gs, sheets/ lig _	NONE			
5.		-			mendments had not bee Supplemental Box (Ru		y have been considered to go
		nt sheets which ion as "origina		shed to the rece	riving Office in response	to an invitation un	der Article 14 are referred to

WRITTEN OPINION

International application No.

		ent	
1. statement			
Novelty (N)	Claims	3-41	YES
	Claims	1-2	_ NO
			VEC
Inventive Step (IS)	Claims Claims	3-41 1-2	
	Claims	1-2	_ 110
			VEC
Industrial Applicability (IA)	Claims Claims	NONE	
	Clamis	None	_ 110
(col 9, line 7+) pharmaceutical composition The claims are drawn to compositions that receptors or ligands. The claims are of su anticipated.	contain peptides officient scope to Article 33(2)-(3)	of 1, lines 9-10) binding of selectins. The reference also to the peptides are effective to modulate binding of selection encompass the peptides disclosed by Heavner; the claim because the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly suggest the compassion of the prior art does not teach or fairly su	etins to ms are

WRITTEN OPINION

International application No.

PCT/US99/26277
ufficient)
Sheet 10
e extended. 37 CFR 1.484(d). Any response will not be considered in preparing the International
•

PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: MARY E. BAK HOWSON AND HOWSON SPRING HOUSE CORPORATE CENTER P.O. BOX 457 SPRING HOUSE, PA 19477

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

IMPORTANT NOTIFICATION

Date of Mailing (day/month/year)

05 MAR 2001

Applicant's or agent's file reference

WST93PCT

International filing date (day/month/year)

Priority Date (day/month/year)

PCT/US99/26277

International application No.

05 NOVEMBER 1999

06 NOVEMBER 1998

Applicant

THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID LUKTON

Telephone No. (703) 308-0196

Budger for

Form PCT/IPEA/416 (July 1992)*

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WST95PCT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form
International application No.	International filing date (day/	/month/year) Priority date (day/month/year)
PCT/US99/26277	05 NOVEMBER 1999	06 NOVEMBER 1998
International Patent Classification (IPC IPC(7): A61K 38/10 and US Cl.: 514		IPC
Applicant THE WISTAR INSTITUTE OF ANA	ATOMY AND BIOLOGY	
Examining Authority and is 2. This REPORT consists of a This report is also accon	s transmitted to the applicant total of sheets. appared by ANNEXES, i.e., she	is been prepared by this International Preliminary int according to Article 36. neets of the description, claims and/or drawings which have sheets containing rectifications made before this Authority
(see Rule 70.16 and Sect	tion 607 of the Administrative l	Instructions under the PCT).
These annexes consist of a to	otal of <u>//</u> sheets.	
3. This report contains indication	ns relating to the following is	items:
I 🙀 Basis of the repo	ort	
II Priority		
ا ا		to the state of th
III Non-establishme	nt of report with regard to no	novelty, inventive step or industrial applicability
IV Lack of unity of	invention	
V X Reasoned statement citations and explain	nt under Article 35(2) with reg anations supporting such staten	gard to novelty, inventive step or industrial applicability, ment
VI Certain documents	cited	
VII Certain defects in	the international application	
VIII Certain observation	ns on the international applicat	ation
Sorial Social		
		•
Date of submission of the demand	Date	te of completion of this report
01 JUNE 2000		20 FEBRUARY 2001
Name and mailing address of the IPEA Commissioner of Patents and Trades Box PCT Washington, D.C. 20231	marks	thorsed officer Budger / Savid LUKTON
Facsimile No. (703) 305-3230	Tele	rephone No. (703) 308-0196

International application No.

I.	B	ASIS (of the rep	ort				
1.	With	rega	nd to the ele	ements of the inter	mational applicati	on:*		
	\mathbf{x}			nal application a				
	二		description		originari, ri	.00		
	X		es					
			es					, as originally filed
			es			filed with th	- 1	, filed with the demand
		Pag.				, med with th	e letter of	
	x	the	claims:					
		page	es	57-63				, as originally filed
		page	es	NONE		, as amended	together with any	statement) under Article 19
			es	NONE				filed with the demand
		page	es	NONE	, filed w	ith the letter of		
r	_	.,						
L	X		drawings:	1-5				
		-	es					, as originally filed
			es	NONE		61 1 1 1		, filed with the demand
		page	es	NONE		, filed with the	letter of	
٢	x	the s	sequence li	sting part of the	description:			
L			es	4 4 4	-			, as originally filed
								, filed with the demand
		page	s	NONE		filed with the l	etter of	, med with the demand
	Thes	e eler the la	ments were anguage of anguage of	available or furnif a translation f f publication of	ished to this Aut furnished for the the internation	ne purposes of int	ng language ernational search (nder Rule 48.3(b))	which is: (under Rule 23.1(b)).). amination (under Rules 55.2 and/
3.	With	rega	ard to any i	nucleotide and/	or amino acid	sequence disclosed	l in the internationa	al application, the international
	prel	imina	ıry examin	ation was carrie	d out on the ba	isis of the sequenc	e listing:	•
	X,	conta	ined in the	e international	application in	printed form.		
۲	_					on in computer re	eadable form.	
Ē				quently to this		_		
Ē	\exists	furni	shed subse	quently to this	Authority in c	omputer readable	form.	
Ī	= :	The s	statement th	hat the subseque	ntly furnished	written sequence li	sting does not go b	beyond the disclosure in the
	7:	The s		plication as filed at the information			rm is identical to the	e writen sequence listing has
4 E	x	The	amendmen	its have resulted	d in the cancel	lation of:		
	_ [x	the descri	iption, pages	NONE			
	Ī	X		s, Nos.	NONE			
	Ī	x		ngs, sheets/ fig				
<i>5</i> . Г	٦,	— This				endments had not b	saan mada amaa th -	y haya baan sanaidan 1+
L						endments had not t Supplemental Box		y have been considered to go
ir	ı thi	cemei	u sheets who	ich have been furi	nished to the reco	eiving Office in respo	onse to an invitation	under Article 14 are referred to tain amendments (Rules 70.16
**/	Iny i	replac	cement shee	et containing such	h amendments n	nust be referred to	under item 1 and a	innexed to this report.

International application No.

. statement			
Novelty (N)			
Novelty (N)	Claims	5-41	YE
	Claims	1-2	NC
Inventive Step (IS)	Claims	3-41	_ YE
	Claims	1-2	
Industrial Applicability (IA)	Claims	1-41	YE
	Claims	NONE	
citations and explanations (Rule 7 Claims 1-2 lack novelty under PCT Article		anticipated by Usawa (UCD common)	
		all 1, lines 9-10) binding of selectins. The reference als	o teaches
receptors or ligands. The claims are of su anticipated.	fficient scope t	s; the peptides are effective to modulate binding of se o encompass the peptides disclosed by Heavner; the c	lectins to laims are
or absociated methods.		(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
or absociated methods.	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	
Claims 1-41 meet the criteria set out in PCI	Article 33(4)	(3), because the prior art does not teach or fairly sugg	

International application No.

Supplemental Box (To be used when the space in any of the preceding boxes is	not sufficient)	
Continuation of: Boxes I - VIII	Sheet	10
		1

PCT DECHIEST

For receiving Office use only
International Application No.
International Filing Date
Name of receiving Office and "PCT International Application"
Applicant's or agent's file reference


REQUEST	International Filing Date			
The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.	Name of receiving Office	and "PCT International Application"		
	Applicant's or agent's file (if desired) (12 characters ma	reference uximum) WST93PCT		
Box No. 1 TITLE OF INVENTION				
COMPOSITIONS AND METHODS FOR TR	EATMENT OF CA	ANCER		
Box No. II APPLICANT				
Name and address: (Family name followed by given name; for a designation. The address must include postal code and name of coa address indicated in this Box is the applicant's State (that is, country of residence is Indicated below.)	legal entity, full official intry. The country of the e) of residence if no State	This person is also inventor.		
The Wistar Institute of Anatomy	and Biology	Telephone No. 215-898-3763		
3601 Spruce Street		Facsimile No.		
Philadelphia, Pennsylvania 191	04	215-573-2456		
United States of America		Teleprinter No.		
		Telefamet 140.		
State (that is, country) of nationality:	State (that is, country) of	residence:		
United States of America	United Stat	tes of America		
	ed States except the states of America of	United States America only the States indicated in the Supplemental Box		
Box No. III FURTHER APPLICANT(S) AND/OR (FURT				
Name and address: (Family name followed by given name: for a designation. The address must include postal code and name of coa address indicated in this Box is the applicant's State (that is, country of residence is indicated below.) The Trustees of the University of Posta 3700 Market Street, Suite 300 Philadelphia, Pennsylvania 19104-3 United States of America	ennsylvania	This person is: x applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)		
State (that is, country) of nationality:	State (that is, country) of	residence:		
United States of America	United Sta	ed States of America		
		United States		
X Further applicants and/or (further) inventors are indicated	on a continuation sheet.			
Box No. IV AGENT OR COMMON REPRESENTATIVE	e; OR ADDRESS FOR C	ORRESPONDENCE		
The person identified below is hereby/has been appointed to act of the applicant(s) before the competent International Authorities	on behalf x as:	gent common representative		
Name and address: (Family name followed by given name: for designation. The address must include postal c	a legal entity, full official code and name of country.)	Telephone No 215-540-9200		
Bak, Mary E.				
Howson and Howson		Facsimile No		
Spring House Corporate Center		215-540-5818		
P.O. Box 457		Teleprinter No		
Spring House, Pennsylvania 19477				
United States of America Address for correspondence: Mark this check-box where	no avent or common repres	sentative is/has been appointed and the		
space above is used instead to indicate a special address to	which correspondence show	ald be sent.		

		2	
Sheet	No.	_	

Continuation of Box No. III FURTHER APPLICANT(S) AN	ND/OR (FURTHER) IN	VENTOR(S)
If none of the following sub-boxes is used, thi	s sheet should not be in	cluded in the request.
Name and address: (Family name followed by given name: for a le designation. The address must include postal code and name of count address indicated in this Box is the applicant's State (that is, country) of residence is indicated below.)	gal entity, full official ry. The country of the of residence if no State	This person is:
Blaszczyk-Thurin, Magdalena 28 University Mews Philadelphia, Pennsylvania 19104 United States of America		x applicant and inventor inventor only (If this check-box is marked, do not fill in below.)
	State (that is, country) of	residence:
State (that is, country) of nationality: United States of America	United States	of America
min annual is applicant all designated all designated	States except	United States the States indicated in the Supplemental Box
Name and address: (Family name followed by given name; for a leading of the address must include postal code and name of coun address indicated in this Box is the applicant's State (that is, country) of residence is indicated below.) Kieber-Emmons, Thomas 3231 Saw Mill Road Newtown Square, Pennsylvania 19073 United States of America	gal entity, full official iry. The country of the of residence if no State	This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)
State (that is, country) of nationality:	State (that is, country) of	
United States of America This person is applicant all designated all designated the Hourd States.	United States States except these of America X of	e United States the States indicated in the Supplemental Box
Name and address: (Family name followed by given name; for a ladsignation. The address must include postal code and name of couraddress indicated in this Box is the applicant's State (that is, country) of residence is indicated below.)	egal entity, full official viry. The country of the of residence if no State	This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)
State (that is, country) of nationality:	State (that is, country) o	f residence:
This person is applicant all designated for the purposes of:		the United States the States indicated in the Supplemental Box
Name and address: (Family name followed by given name: for a designation. The address must include postal code and name of cou address indicated in this Box is the applicant's State (that is, country of residence is indicated below.)	legal entity, full official ntry. The country of the) of residence if no State	This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)
State (that is, country) of nationality:	State (that is, country)	
This person is applicant all designated states all designated the United states.	ed States except States of America	the United States of America only the Supplemental Box
Further applicants and/or (further) inventors are indicated	on another continuation	See Notes to the request for

Box N	o.V	DESIGNATION OF STATES			
The fo	llowi	ng designations are hereby made under Rule 4.9(a) (m	ark the	appli	cable check-boxes, at least one must be marked):
Regio	nal Pe	atent			
		I'C Haanda ZW Zunbabwe and any other State w	men c) u (MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, ontracting State of the Harare Protocol and of the PCT
	EA	Moldova, RU Russian Federation, 13 Talikistan, 13	vi iui	KILICII	s, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of istan, and any other State which is a Contracting State
X	EP	European Patent: AT Austria, BE Belgium, CH a DK Denmark, ES Spain, FI Finland, FR France, GB of MC Monaco, NL Netherlands, PT Portugal, SE Sweet Peters Convention and of the PCT	den, an	id any	tzerland and Liechtenstein, CY Cyprus, DE Germany, dom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, other State which is a Contracting State of the European
	OA	GA Gabon, GN Guinea, GW Guinea-Bissau, ML Ma	d a Co	ntraci	Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, ritania, NE Niger, SN Senegal, TD Chad, TG Togo, and ting State of the PCT (if other kind of protection or treatment
Nation	al Pate	nt (if other kind of protection or treatment desired, specify	on dott	ed lin	2):
		United Arab Emirates			Liberia
		Albania		LS	Lesotho
		Armenia		LT	Lithuania
		Austria	$\overline{\Box}$	LU	Luxembourg
		Australia	$\bar{\Box}$		Latvia
		Azerbaijan	$\overline{\Box}$		Republic of Moldova
][Bosnia and Herzegovina			Madagascar
	BB	Barbados		MK	The former Yugoslav Republic of Macedonia
	BG	Bulgaria		,,,,,,	
		Brazil		MN	Mongolia
			H		V Malawi
	BY		=	MAN	Mexico
		Canada and L1 Switzerland and Liechtenstein			
		China			Norway New Zealand
	CU			PL	Portugal
		Czech Republic		PT	
		Germany			Romania Russian Federation
		Denmark			
		Estonia		SD	Sudan
1	ES	Spain		SE	Sweden
1 4	FI	Finland		SG	Singapore Slovenia
	GB	_		SI	Slovakia
		Grenada	ᆜ		Sierra Leone
		Georgia		SL	
		Ghana		TJ	Tajikistan
	GN	1 Gambia		TN	Turkmenistan
🖳	HR	Croatia			Turkey
	HU			TT	
	ID	Indonesia			Ukraine
	IL	Israel		UG	Uganda (Amarica
	IN	India	\boxtimes	US	United States of America
	IS	Iceland	_		
X		Japan		UZ	Uzbekistan ,
					Viet Nam
		Kyrgyzstan			Yugoslavia
[] KI			ZA	
				ZV	V Zimbabwe
		Republic of Korea	CF be	ieck-ł come	party to the PCT after issuance of this sheet:
		Kazakhstan			
		Saint Lucia			
		Sri Lanka	matica	ne ma	de above, the applicant also makes under Rule 4.9(b) all other
from desi	gnatic n the : gnatio	scope of this statement. The applicant declares that	those onths fi	additi rom th	ional designations are subject to confirmation and that any ne priority date is to be regarded as withdrawn by the applicant of filing of a notice specifying that designation and the payment of the within the 15-month time limit.)
Form	PCT/	RO/101 (second sheet) (July 1999)			See Notes to the request for

If the Supplemental Box is not used, this sheet should not be included in the request.



- (i) If more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
- (ii) if in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
- (v) if, in Box No. 1', the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or "in Box No. 1', the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. 1'" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
- (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
- (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.
- 2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.
- 3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

"Continuation of Box No. IV"

Kita, Stanley B. Smith, George A., Jr. Kodroff, Cathy A. Bak, William

All above attorneys are members of the firm of Howson and Howson. Address of all is indicated in Box ${\ \rm IV.}$

Sheet No. 5.....

item (1) 06 November 1998 60 (06.11.98) item (2) item (3) X The receiving Office is requested of the earlier application(s) (on purposes of the present internal where the earlier application is an AB Convention for the Protection of Industri	tional application is the RIPO application, it is mail Property for which the L SEARCHING AUT Authority (ISA) Reg Authorities are all search, indicate	he receiving Office) identif andatory to indicate in the Su at earlier application was file	pplemental Box at least on d (Rule 4.10(b)(ii)). See Su	international application: receiving Office 1 e country party to the Paris applemental Box.
item (1) 06 November 1998 60 (06.11.98) item (2) item (3) Item (3) Item (3) Item (4) Item (5) Item (6) Item (7) Item (8) Item (9) Item (1) Item (ed to prepare and trans thy if the earlier applicational application is the last property for which the L SEARCHING AUT Authority (ISA) Research search indicate	country United States of America mit to the International Bucation was filed with the erceiving Office) identificand across to indicate in the State earlier application was file THORITY	regional Office Treau a certified copy Office which for the lied above as item(s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemental Box at least on the lied above as item (s) # Upplemen	receiving Office 1 e country party to the Paris applemental Box.
item (3) The receiving Office is requested of the earlier application (s) (on purposes of the present internated Where the earlier application of Industry Box No. VII INTERNATIONAL Choice of International Searching of the property of the international Searching of the property of the international Searching of the property of the international Searching of the internat	ed to prepare and trans aly if the earlier application is the RIPO application, it is mail Property for which the L SEARCHING AUT Authority (ISA) 18 Authorities are 21 search, indicate	of America mit to the International Bucation was filed with the he receiving Office) identifiandatory to indicate in the Suat earlier application was file	pplemental Box at least on d (Rule 4.10(b)(ii)). See Su	e country party to the Paris upplemental Box.
item (2) Item (3) The receiving Office is requested of the earlier application(s) (or purposes of the present internated with the earlier application is an AB Convention for the Protection of Industry Box No. VII INTERNATIONAL Choice of International Searching of the protection of International Searching and the earlier and the international Searching and the convention to c	tional application is the RIPO application, it is mail Property for which the L SEARCHING AUT Authority (ISA) Reg Authorities are all search, indicate	the receiving Office) identificand arony to indicate in the Swat earlier application was file THORITY	pplemental Box at least on d (Rule 4.10(b)(ii)). See Su	e country party to the Paris upplemental Box.
The receiving Office is requested of the earlier application(s) (on purposes of the present internated with the earlier application is an AF Convention for the Protection of Industrial Box No. VII INTERNATIONAL Choice of International Searching of the or more international Searching convention to carry out the international Searching of the or more purpose.	tional application is the RIPO application, it is mail Property for which the L SEARCHING AUT Authority (ISA) Reg Authorities are all search, indicate	the receiving Office) identificand arony to indicate in the Swat earlier application was file THORITY	pplemental Box at least on d (Rule 4.10(b)(ii)). See Su	e country party to the Paris upplemental Box.
purposes of the present internate Where the earlier application is an AF Convention for the Protection of Industria. Box No. VII INTERNATIONAL Choice of International Searching of two or more International Search of the property of the international Search.	tional application is the RIPO application, it is mail Property for which the L SEARCHING AUT Authority (ISA) Reg Authorities are all search, indicate	the receiving Office) identificand arony to indicate in the Swat earlier application was file THORITY	pplemental Box at least on d (Rule 4.10(b)(ii)). See Su	e country party to the Paris upplemental Box.
Box No. VII INTERNATIONAL Choice of International Searching of two or more International Searching company to carry out the international	L SEARCHING AUT Authority (ISA) Re al search, indicate	THORITY	rlier search: reference	
Box No. VII INTERNATIONAL Choice of International Searching of two or more International Search compagnity to carry out the international	Authority (ISA) Re al search, indicate	THORITY	rlier search: reference	
(if two or more International Searching	ig Authorities are seas	quest to use results of ear rch has been carried out by or	rlier search: reference	to that search lif an earlier
me manority ended the two tener code	,	te (day month year)	requested from the Internal Number	tional Searching Authority): Country (or regional Office)
ISA/US				
Box No. VIII CHECK LIST; L.	1			
This international application contains the following number of sheets:	ins This internation 1. fee calcu	al application is accompa- lation sheet	nied by the item(s) mark	ed below:
request : 5 description (excluding		signed power of attorney		
sequence listing part) : 56		general power of attorney;		y:
claims : 7		at explaining lack of signat		
abstract : 1		document(s) identified in I		
drawings : 5		on of international applicat		or other biological material
sequence listing part of description : 36	7. Separate	de and/or amino acid seque	ence listing in computer	readable form
Total number of sheets: 110		pecify): Transmittal		
Figure of the drawings which should accompany the abstract:	L	anguage of filing of the ternational application:	English	
Box No. IX SIGNATURE OF	APPLICANT OR AG	GENT		
Next to each signature, indicate the name of		capacity in which the person sig	gus (if such capacity is not obv	vious from reading the request).
By: Mary E. Bak Attorney for				
Date of actual receipt of the pur international application:		receiving Office use only		2. Drawings:
Corrected date of actual receipt timely received papers or drawing.	ings completing			received:
the purported international appl 4. Date of timely receipt of the recorrections under PCT Article	quired			not received:
5. International Searching Authori (if two or more are competent):	ity ICA /	6. Transm	ittal of search copy delay arch fee is paid.	ed